Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2023-09-20 00:00:00 ET · period of report 2023-09-18 · accession 0001209191-23-050173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-20 | 2023-09-18 | DYN | McNeill Jonathan | Chief Business Off | S - Sale | $9.41 | -1,261 | 60.6K | -2% | -$11.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-18 | S | D | 1,261 | $9.41 | 60,605 | D | — | — | (F1) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. (F2) Includes 50,991 unvested RSUs. |